Posts Tagged ‘Pharma’

Innovieren für preisbewusste Kunden: Analogieeinsatz als Erfolgsfaktor in Schwellenländern

Monday, October 21st, 2013
An artfical heart developed by IIT Kharagpur based on an analogy  to a cockroach's heart. Photo courtsey: Times of India
An artfical heart developed by IIT Kharagpur based on an analogy to a cockroach’s heart. Photo courtsey: Times of India

Neue Publikation vom Center for Frugal Innovation @TIM/TUHH: Ein neues Arbeitspapier von Rajnish Tiwari und Cornelius Herstatt (Working Paper No. 75, TIM/TUHH) untersucht den EInsatz von innovativen Produktanalogien in frugalen Innovationsprojekten und kommt zum Schluss, “dass frugale Innovationen aufgrund der hohen Bedeutung von Risikominimierung in Produktentwicklungsprojekten häufig eine größere Offenheit für externes Wissen und Analogien aus ihrer Umwelt aufweisen, und davon auch viel profitieren. Den interessierten (potenziellen) frugalen Innovatoren kann diese Methode daher zwecks Reduzierung von Entwicklungskosten und –risiken aber auch zur Steigerung der Prozesseffizient empfohlen werden. Nicht zuletzt zeigen die Fallstudien aber auch, dass der Analogieeinsatz in frugalen Innovationen wichtige Erkenntnisse fürs Management von Innovationsprojekten in nicht-frugalem Bereich liefern kann.”

(more…)

India orders ‘compulsory license’ for Bayer’s cancer drug

Tuesday, March 13th, 2012

According to one report in the Economic Times (13.03.2012):

The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany’s Bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry’s anxiety over the use of the controversial compulsory licensing provision.

The outgoing patent controller of India, PH Kurian, on Monday granted the country’s first compulsory licence to Hyderabad-based Natco Pharma, permitting it to manufacture and market a generic version of Nexavar, a medicine used for treating liver and kidney cancer, in India for just 3% of the patented drug’s price in return for paying 6% royalty on sales to Bayer.

[…] Bayer is expected to legally challenge the decision. “We will evaluate our options to further defend our intellectual property rights in India,” a company spokesman said. […]

Source: “Natco Pharma bags licence to sell Bayer’s cancer drug Nexavar” (Economic Times, 13.03.2012)

Also see: “India patent ruling may open door for cheaper HIV drugs” (Economic Times, 13.03.2012)

Report forecasts global spending on medicines to cross $1.1 trillion by 2015

Tuesday, June 21st, 2011

Press Release

Slowing Growth in Developed Markets as Patent Expiries and Policy Changes Take Hold

PARSIPPANY, NJ, May 18, 2011 – The IMS Institute for Healthcare Informatics today reported that global spending for medicines will reach nearly $1.1 trillion by 2015, reflecting a slowing compound annual growth rate of 3-6 percent over the next five years. This compares with 6.2 percent annual growth over the past five years. Lower levels of spending growth for medicines in the U.S., the ongoing impact of patent expiries in developed markets, continuing strong demand in pharmerging markets, and policy-driven changes in several countries are among the key factors that will influence future growth, according to the IMS Institute’s new study, The Global Use of Medicines: Outlook Through 2015.

“The future level of spending on medicines has striking implications for healthcare systems and policy makers across the developed and emerging economies,” said Murray Aitken, executive director, IMS Institute for Healthcare Informatics. “Past patterns of spending offer few clues about the level of expected growth through 2015. There are unprecedented dynamics at play, which are driving rapid shifts in the mix of spending by patients and payers between branded products and generics, and across both developed and pharmerging markets.”

In its latest analysis, the IMS Institute identifies the following dynamics:

  • Brands accelerate their decline in share of spending. While aging populations in developed markets will continue to drive incremental spending on brands, this will be more than offset by the impact of patent expiries. As a result, spending for branded products in developed markets will remain at the same level in 2015 as in 2010. Globally, market share for branded medicines, which fell from 70 percent in 2005 to 64 percent in 2010, is expected to decline further through 2015, to 53 percent. While growth for branded products in the emerging markets will be robust, 80 cents of every dollar spent on medicines in these markets in 2015 will be for generics.
  • Unprecedented level of patent expiries brings “patent dividend” to developed markets. Expiring patents for branded products will yield $98 billion in net savings to payers in developed countries through 2015, compared with $54 billion in savings realized in the five years to 2010. Patent expiries will save payers $120 billion by 2015, offset by $22 billion of expected generic spending for these medicines. Among developed markets, the U.S. will experience the largest expansion of generic spending, while Japan will continue to have the lowest share despite significant policy incentives to increase generic prescribing and dispensing.
  • Novel therapies address unmet patient needs. Recent and upcoming launches of new medicines will bring important new treatment options to extend or improve patients’ quality of life. These include: oral medications for multiple sclerosis with increased efficacy and patient convenience; two recently launched treatments for arrhythmia that expand therapy options for the first time in decades; treatments for metastatic melanoma that improve survival rates; and the first therapeutic prostate cancer vaccine, a breakthrough advance in personalized medicine.
  • Pharmerging markets approach U.S. levels of spending on medicines. Over the next five years, the pharmerging markets are expected to nearly double their spending on medicines, to $285-315 billion, compared with $151 billion in 2010. This will be fueled by strong economic growth and governments’ commitment to expanded healthcare access. The IMS Institute forecasts that by 2015, the pharmerging markets will become the second largest geographic segment globally in spending on medicines – surpassing Germany, France, Italy, Spain and the U.K. combined, and approaching U.S. levels.
  • Health policy decisions affect spending in the long term. 2010 policy decisions that will affect spending for medications during the next five years include: the passage of the Affordable Care Act in the U.S., which will expand health insurance coverage to 25-30 million Americans; price controls in China to ensure the sustainability of universal coverage; Japan’s first price cut under its new protected innovative products policy; price reductions to generics and off-patent products in Spain and Italy; and mandatory cost-benefit evaluations for new products in Germany. Additionally, rebates and discounts, which are not reflected in IMS audits, are being applied more extensively by public and private payers, particularly in the U.S., France and Germany. The amount of these off-invoice discounts in 2010 is estimated to be $60-65 billion, and will rise to $65-75 billion by 2015.
  • Biosimilars evolve rapidly, but adoption limited. By 2015, the IMS Institute expects spending on biosimilars to exceed $2 billion annually, or about 1 percent of total global spending on biologics. New biosimilars are expected to enter the U.S. market by 2014, and European markets will see additional biosimilar molecules introduced during this period. This will accelerate spending for biosimilars over the 2010 level of $311 million.

The IMS Institute also identified the leading therapeutic classes in 2015. These include: Oncology, which is expected to remain the leading therapy class but with slowing growth of 5-8 percent as existing targeted therapies already have been widely adopted; diabetes treatments, where spending is forecast to be 4-7 percent, driven by the rising prevalence of the disease and by the uptake of newer oral antidiabetic agents; asthma and COPD treatments, where growth is expected to slow to 2-5 percent; and lipid regulators, where spending will fall to $31 billion in 2015 from $37 billion in 2010

Said Aitken, “Over the next five years, we’ll not only see total spending exceed $1 trillion, but payers will be managing a significant patent dividend while emerging market governments seek to expand treatment options to more patients. All of this will require that healthcare stakeholders engage in a truly meaningful dialogue as they seek the common goal of increased access, cost reductions and better outcomes.”

To access the IMS Institute report, The Global Use of Medicines: Outlook Through 2015, go to http://www.theimsinstitute.org. The study also features additional details related to global country rankings, spending on medicines in the developed and pharmerging markets, and forecast summaries on spending by country.

Analyses conducted for The Global Use of Medicines: Outlook Through 2015 report are based on IMS audits and include all types of biopharmaceuticals, including biologics, OTC, and traditional medicines distributed and administered through regulated delivery systems such as pharmacies, hospitals, clinics, physician offices, and mail order, where applicable. Spending figures are derived from IMS Market Prognosis™ and are reported at ex-manufacturer estimated prices that do not reflect off-invoice discounts and rebates. IMS MIDAS™, Lifecycle™ R&D Focus, Lifecycle™ New Product Focus, PharmaQuery™ and Therapy Forecaster™ were also used for assessing worldwide healthcare markets, therapy class and product dynamics and country-level pricing and reimbursement complexities. More detail on information sources is included in the report.

About the IMS Institute for Healthcare Informatics
The IMS Institute for Healthcare Informatics provides key policy setters and decision makers in the global health sector with unique and transformational insights into healthcare dynamics derived from granular analysis of information. It is a research-driven entity with a worldwide reach that collaborates with external healthcare experts from across academia and the public and private sectors to objectively apply IMS’s proprietary global information and analytical assets. More information about the IMS Institute can be found at: http://www.theimsinstitute.org.

—–

Source of this press release: Click here

‘Partnering for Success’ – Roche partners with Mahindra Satyam

Thursday, May 26th, 2011

(Source: Press release from Mahindra Satyam, dated: 19.05.2011)

Hyderabad, India – May 19, 2011: Mahindra Satyam, a leading global consulting and IT services provider, today announced that it has inaugurated the Roche Offshore Delivery Center (ODC) at Hyderabad.

Christian Hebich, Global Head, IT End-User & Operations Services, Roche, inaugurated the state-of-the-art ODC which will be housed in Mahindra Satyam’s Infocity campus at Hyderabad. The Center will deliver services on application development, testing, project management, communications and training to support the design, build and deployment of IT Lifecycle Services.

“‘Partnering for Success’ reflects our organizational commitment to seamlessly collaborate with Roche IT and treat their end-customers as our own. Our acknowledged and proven excellence in delivery quality will be leveraged even further, to support Roche’s accelerated business growth,” said Vikram Nair, Senior Vice President & Head, Mahindra Satyam Europe.

The ODC inauguration is the beginning of a partnership between the two enterprises in the domain, which started with collaborative delivery of multiple services for the Process Alignment Program (PAP) to support the IT Lifecycle Services at the beginning of 2011.

The successful ‘Go-Live’ of the alignment project in 101 countries including Turkey, Brazil, United States, Switzerland, Germany, Greece, Poland, South Africa and India began in January this year.

“We are extremely pleased that Roche is partnering with Mahindra Satyam. This partnership enables us to create and deliver additional value to customers. This clearly demonstrates the growing confidence Roche has in the Knowledge-based IT Industry in India.” said Dr. Girish Telang, Vice-Chairman & Managing Director, Roche Products (India) Pvt. Ltd.

About Roche, India

Roche Products (India) Pvt. Ltd. (formerly known as Roche Scientific Company (India) Pvt. Ltd. was incorporated in India in April, 1994. Roche has made personalised healthcare the cornerstone of its innovative strategy and the main focus is to bring clinically differentiated medicines to address unmet medical needs in the treatment of cancer and other complex diseases for the benefit of patients. With a patient-centric approach in mind, Roche in India has achieved the status of scientific leadership in the fields of Oncology, Transplantation & Anaemia, Virology and Rheumatology. Towards fulfilling the above objectives, the Company has focused its activities towards:-

  • Disseminating scientific and other information regarding availability and accessibility of Roche products and creating awareness among the medical fraternity, hospitals, institutions and patient community in India;
  • Marketing support services for all Roche products in India.
  • Ensuring registration of new products with the Health Authorities.
  • Supporting clinical trials in all therapeutic areas in compliance with applicable legislation.

For more information: www.roche.com

About Mahindra Satyam

Mahindra Satyam is a leading global business and information technology services company that leverages deep industry and functional expertise, leading technology practices, and an advanced, global delivery model to help clients transform their highest-value business processes and improve their business performance.

The company’s professionals excel in enterprise solutions, supply chain management, client relationship management, business intelligence, business process quality, engineering and product lifecycle management, and infrastructure services, among other key capabilities.

Mahindra Satyam is part of the $11.1 billion Mahindra Group, a global industrial federation of companies and one of the top 10 business houses based in India. The Group’s interests span automotive products, aviation, components, farm equipment, financial services, hospitality, information technology, logistics, real estate and retail.

Mahindra Satyam IMS is a leader in offering innovative and transformational infrastructure services to enterprises helping them build and manage their IT infrastructure more efficiently and effectively.

Mahindra Satyam development and delivery centers in the US, Canada, Brazil, the UK, Hungary, Egypt, UAE, India, China, Malaysia, Singapore, and Australia serve numerous clients, including many Fortune 500 organizations.

For more information, see www.mahindrasatyam.com

Follow us on Twitter: http://twitter.com/mahindra_satyam

For clarifications, write to us at: MediaRelations@mahindrasatyam.com

Carl Zeiss Meditec Opens Center for Application and Research in Bangalore, India

Tuesday, February 8th, 2011

CARIn (Center of Application & Research in India) focuses on research in the field of ophthalmology

JENA/Germany, 07.02.2011.
Carl Zeiss Meditec has opened its Center for Application and Research (CARIn) in India this weekend. With this move, Carl Zeiss Meditec is strengthening its presence in high growth markets like India and targeting its investments at research and development projects. Carl Zeiss has already been represented with its own sales and service company in the country’s large urban centers since 1997.

Dr. Michael Kaschke, President and CEO of Carl Zeiss AG and responsible for the Asia region on the Executive Board, since 1 January 2011, comments on the opening of CARIn as follows: “Carl Zeiss has been active in India for more than ten years. However, for our company the country is more than a sales market: our customer base, as well as the industrial and research landscapes, have a lot more to offer. Therefore, in India we are investing not only in the expansion of our sales and service network, but also in product and application development. In this process, we are working very closely with our customers and partners in science.”

“Innovations form the foundation of our strategy that makes the latest medical technology available to high growth markets like India,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “In the past, we already succeeded in developing products tailored specifically to the needs of doctors in these countries. With our own Center of Application and Research in India and a team of highly motivated staff, we can work even more closely with customers on site and integrate their needs even more effectively into our product developments.”

Research and development activities of CARIn at a glance:

  • Define products for Rapidly Developing Economies (RDE), i.e. growth markets like India or China
  • Develop new products for these markets, in particular software and solutions that enhance workflow efficiency in doctors’ offices and hospitals
  • Develop clinical applications and studies
  • Collaborate closely with medial research institutes, hospitals and universities in India in order to jointly develop medical techniques and solutions

CARIn – Facts and figures
CARIn, the Center of Application & Research in India, is located in the immediate vicinity of the Carl Zeiss sales and service company in Bangalore. The research and development work will initially be focused on systems for use in ophthalmology. Over the long term, however, the R&D activities will be expanded to include the entire product spectrum of Carl Zeiss Meditec. The first employees for the new center have already been recruited. The capacity will be expanded to up to 50 staff in the mid term.

CARin
Image Download (JPG: 2.0 MB)
CARIn, the new Centre of Application and Research of Carl Zeiss Meditec in Bangalore, India

Eva Sesselmann
Group Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331
Fax: +49 3641 220-112
E-Mail: press@meditec.zeiss.com

Patrick Kofler
Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-106
Fax: +49 3641 220-117
E-Mail: investors@meditec.zeiss.com

Number: 0014-2011-ENG OP

Source: http://www.zeiss.de/C1256A770030BCE0/WebViewTopNewsAllE/7D9C54AB8EEA5A51C125783000390A7A?OpenDocument